Document is current
Any future updates will be listed below
-
Authors
Holay, Nisha https://orcid.org/0000-0003-4363-3521
Yadav, Rashi
Ahn, Sae Jeong
Kasiewicz, Melissa J
Polovina, Anya
Rolig, Annah S https://orcid.org/0000-0001-7080-4352
Staebler, Thi
Becklund, Bryan
Simons, Noah D
Koguchi, Yoshinobu
Eckelman, Brendan P
de Durana, Yaiza Diaz
Redmond, William L https://orcid.org/0000-0002-2572-1731
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04198766 at ClinicalTrials.govnct04198766 at ClinicalTrials.govDocuments that mention this clinical trial
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0748
1301 Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
https://doi.org/10.1136/jitc-2024-sitc2024.1301
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
https://doi.org/10.1136/jitc-2025-011524
651 Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 as an add-on to pembrolizumab in first-line recurrent/metastatic PD-L1+ (combined positive score ≥20) head and neck cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0651
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
https://doi.org/10.1136/jitc-2023-sitc2023.1360
nct04198766 at ClinicalTrials.govDocuments that mention this clinical trial
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0748
1301 Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
https://doi.org/10.1136/jitc-2024-sitc2024.1301
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
https://doi.org/10.1136/jitc-2025-011524
651 Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 as an add-on to pembrolizumab in first-line recurrent/metastatic PD-L1+ (combined positive score ≥20) head and neck cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0651
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
https://doi.org/10.1136/jitc-2023-sitc2023.1360
nct04198766 at ClinicalTrials.govDocuments that mention this clinical trial
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0748
1301 Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
https://doi.org/10.1136/jitc-2024-sitc2024.1301
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
https://doi.org/10.1136/jitc-2025-011524
651 Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 as an add-on to pembrolizumab in first-line recurrent/metastatic PD-L1+ (combined positive score ≥20) head and neck cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0651
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
https://doi.org/10.1136/jitc-2023-sitc2023.1360
Documents that mention this clinical trial
748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
https://doi.org/10.1136/jitc-2023-sitc2023.0748
1301 Treatment with a novel hexavalent OX40 agonist enhances activation of circulating T cells to favor anti-tumor immunity
https://doi.org/10.1136/jitc-2024-sitc2024.1301
INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering
https://doi.org/10.1136/jitc-2025-011524
651 Phase 2/3 study of the hexavalent OX40 agonist INBRX-106 as an add-on to pembrolizumab in first-line recurrent/metastatic PD-L1+ (combined positive score ≥20) head and neck cancer
https://doi.org/10.1136/jitc-2024-sitc2024.0651
1360 Treatment with a novel hexavalent OX40 agonist remodels the tumor microenvironment to favor anti-tumor immunity in mice
https://doi.org/10.1136/jitc-2023-sitc2023.1360
-
Funding
Funding for this research was provided by:
NIH Office of the Director (S10 OD030417)
M. J. Murdock Charitable Trust (n/a)
Providence Portland Medical Foundation (n/a)
- License Information
